GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Pre-Tax Income

MedMira (MedMira) Pre-Tax Income : $-2.18 Mil (TTM As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. MedMira's pretax income for the three months ended in Jan. 2024 was $-0.44 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jan. 2024 was $-2.18 Mil. MedMira's pretax margin was -396.40%.

During the past 13 years, MedMira's highest Pretax Margin was -31.53%. The lowest was -716.67%. And the median was -225.53%.


MedMira Pre-Tax Income Historical Data

The historical data trend for MedMira's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Pre-Tax Income Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.61 -1.52 -0.54 -1.42 -2.03

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.44 -0.73 -0.57 -0.44

Competitive Comparison of MedMira's Pre-Tax Income

For the Biotechnology subindustry, MedMira's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where MedMira's Pre-Tax Income falls into.



MedMira Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

MedMira's Pretax Income for the fiscal year that ended in Jul. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-1.346+0+-0.671+0+-0.0089999999999995
=-2.03

MedMira's Pretax Income for the quarter that ended in Jan. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.274+0+-0.166+0+5.5511151231258E-17
=-0.44

Pre-Tax Income for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (OTCPK:MMIRF) Pre-Tax Income Explanation

MedMira's Pretax Margin for the quarter that ended in Jan. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-0.44/0.111
=-396.40%

During the past 13 years, MedMira's highest Pretax Margin was -31.53%. The lowest was -716.67%. And the median was -225.53%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of MedMira's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019